Solthis Solidarité Thérapeutique et Initiatives pour la Santé

International solidarity NGO

Created by research physicians,

Solthis contributes to improve health for all

By strengthening health systems

Donate now

HEPATITIS

Laboratoire

The Concerns

Hepatitis B and C are liver infections caused by viruses. Hepatitis B is very contagious and is transmitted mother-to-child, by sexual means, and through blood (transfusions, injuries to healthcare personnel, injections with unclean needles, scarification, etc.). It is estimated that 5% of the world population (350 million people) is infected with hepatitis B. Hepatitis B affects 10% of the population in Sub-Saharan Africa. Hepatitis C affects 170 million people and is primarily transmitted by blood.

Hepatitis B can cause fulminant hepatitis leading to death, but the two forms of hepatitis are particularly responsible for chronic liver infection, occurring in 25% of people infected with hepatitis B and 90% of people with hepatitis C. They also cause cirrhosis and liver cancer. Hepatitis B is the leading cause of cirrhosis worldwide, well ahead of alcohol consumption. The complications from hepatitis B and C are estimated to be responsible for more than a million deaths each year from cirrhosis and liver cancer, with 70% of deaths linked to hepatitis B and 30% linked to hepatitis C.

There is a vaccine that effectively protects against hepatitis B, particularly in newborns of mothers with hepatitis B, and medications to treat infected people. The vaccine must be administered from birth to effectively protect newborns, but this strategy is under-applied. There is no vaccine for hepatitis C, but effective treatments that can cure the majority of infected people have recently been developed. However, they are not widely available, for the time being, due to prohibitive costs.

 

Solthis' action

Passage into the chronic form, with the risk of cirrhosis and liver cancer, is more frequent when the disease is contracted at birth or as a young child. Preventing the transmission of hepatitis B from mother to child is a priority for Solthis. We hope to improve vaccination, particularly in Sierra Leone, and to develop a strategy linking antiviral treatment in the mother with vaccination for the newborn, particularly in Mali.

 

Country action

MALINIGERSIERRA LEONEGUINEA

Expertise

OPERATIONAL RESEARCHCAPACITY BUILDINGADVOCACYSTRENGTHENING SYSTEMS AND HEALTH SERVICESHEALTH SERVICEHEALTH WORKFORCEHEALTH PRODUCTS AND PHARMACEUTICAL SYSTEMLABORATORIES AND TECHNICAL PLATFORMSHEALTH FINANCINGGOVERNANCE AND HEALTH POLICIESHEALTH INFORMATION SYSTEM

Health priority

HIV / AIDSTUBERCULOSISEBOLAMOTHER AND CHILD HEALTHMALARIA

Associated contents

Séroprévalence des virus de l’immunodéficience humaine et des hépatites B et C chez les donneurs de sang à Ségou au Mali

2012 |  Scientific Papers

MALIOPERATIONAL RESEARCHHEPATITIS

Author(s) : M.C. Koné, E.T. Sidibé, K.K. Mallé, S. A. Beye, G. Lurton, M.T. Diarra Journal : Médecine et Santé Tropicales 2012; xx : 1-2. doi : 10.1684/mst.2012.0016

  DOI : 10.1684/mst.2012.0016

3rd Scientific Sessions – Niamey, October 2009

2009

NIGERCAPACITY BUILDINGOPERATIONAL RESEARCHADVOCACYHIV / AIDSTUBERCULOSISHEPATITIS

The Scientific Days, organized by the ULSS and CMT, in partnership with Solthis and GIP Esther, took place on 2 and 3 October 2009 in Niamey in the presence of Professor Katlama (Solthis President), Prof. Brucker (Treasurer Solthis and CEO of Esther) but also of Dr Kassi (Ivory Coast) and Professor Toure (Senegal). More than 250 physicians, health professionals, representatives of the fight against HIV, tuberculosis in Niger attended these days. Many topics on Chess therapeutic Opportunistic Infections, PMTCT, Accidents of exposure to blood and the delegation of tasks were discussed.

 

Get Updates

Subscribe to our newsletter

SUBSCRIBE

Our projects

gifSolthisGB-300x300

RSS Feed | Site map  | © Solthis 2018 - All rights reserved